Segall Bryant & Hamill LLC Has $26.36 Million Holdings in Geron Co. (NASDAQ:GERN)

Segall Bryant & Hamill LLC raised its holdings in shares of Geron Co. (NASDAQ:GERN - Free Report) by 82.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,446,275 shares of the biopharmaceutical company's stock after purchasing an additional 3,369,196 shares during the quarter. Segall Bryant & Hamill LLC owned 1.23% of Geron worth $26,360,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. RTW Investments LP acquired a new stake in shares of Geron during the third quarter worth approximately $200,268,000. Nvest Financial LLC acquired a new position in Geron during the 4th quarter worth $693,000. Janus Henderson Group PLC increased its position in shares of Geron by 140.0% in the 3rd quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company's stock worth $102,193,000 after purchasing an additional 13,163,889 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Geron by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,523,864 shares of the biopharmaceutical company's stock valued at $16,014,000 after buying an additional 73,482 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Geron by 114.9% during the 3rd quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock valued at $5,902,000 after acquiring an additional 694,931 shares in the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

GERN has been the topic of a number of recent research reports. Scotiabank cut their target price on shares of Geron from $6.00 to $4.00 and set a "sector outperform" rating on the stock in a report on Thursday, February 27th. Stifel Nicolaus lowered their target price on shares of Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th. HC Wainwright restated a "neutral" rating on shares of Geron in a report on Wednesday, March 12th. Finally, Barclays restated an "overweight" rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $5.75.

Geron Price Performance

GERN stock remained flat at $1.65 during trading hours on Friday. 16,132,828 shares of the company's stock traded hands, compared to its average volume of 11,244,364. The stock has a market cap of $1.05 billion, a P/E ratio of -5.16 and a beta of 0.53. The stock has a 50 day moving average of $2.29 and a 200 day moving average of $3.38. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. Geron Co. has a 12 month low of $1.46 and a 12 month high of $5.34.

Geron (NASDAQ:GERN - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Sell-side analysts expect that Geron Co. will post -0.25 earnings per share for the current year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.